Case ID: f-supp-3d_215/html/0670-01.html
Source: Caselaw Access Project
Author: {"author": "Elaine E. Bucklo, United States District Judge", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

Stephanie LEINER, on behalf of herself and all others similarly situated, Plaintiff, v. JOHNSON & JOHNSON CONSUMER COMPANIES, INC., Defendants.
    Case 15 C 5876
    United States District Court, N.D. Illinois, Eastern Division.
    Signed 01/12/2016
    
      James B. Zouras, Andrew C. Ficzko, Jorge A Gamboa, Ryan F. Stephan, Stephan Zouras, LLP, Mark Bryan Goldstein, Walker Morton LLP, Perry Evan Gatteg-no, Pomerantz LLP, Chicago, IL, Jayne Goldstein, Shepherd Finkelman Miller & Shah, Ft.Lauderdale, FL, for Plaintiff.
    Daniel Adam Spira, Sidley Austin LLP, Chicago, IL, Jason R. Brost, Carlton Fields Jorden Burt, P.A., Washington, DC, Mark A. Neubauer, Carlton Fields Jorden Burt, LLP, Los Angeles, CA, for Defendants.
   MEMORANDUM OPINION AND ORDER

Elaine E. Bucklo, United States District Judge

Plaintiff Stephanie Leiner complains on behalf of herself and a class that defendant violated the Illinois Consumer Fraud and Deceptive Business Practices Act (“ICFA”) by labeling and advertising two of its products (together, the “Bedtime Bath Products”) as “clinically proven” to help babies sleep better when it knew that the products had not been clinically proven to have that effect. Defendant has moved to dismiss the case and/or to strike plaintiffs’ class allegations. The motion is denied for the following reasons.

Defendant’s lead argument is that plaintiff lacks standing to seek injunc-tive relief, since, no longer fooled by defendants’ deceptive statements, she is not likely to purchase the Bedtime Bath Products again.. Defendant also insists that plaintiff lacks standing to pursue class claims arising out of the purchase of Bedtime Bath Products any time before 2014, when she herself bought the products. I agree with plaintiff, however, that Arreola v. Godinez, 546 F.3d 788 (7th Cir. 2008), reveals the flaw in these arguments. In Arreola, the Seventh Circuit explained that “[although the two concepts unfortunately are blurred at times, standing and entitlement to relief are not the same thing.” Id. at 794-95. Accordingly, while the court of appeals agreed with the district court that the plaintiff — an inmate who was no longer incarcerated at the facility whose conduct he sought to enjoin — had too tenuous an interest in prospective relief to maintain a viable claim for an injunction, id., at 799, it nevertheless concluded that his Article III standing was secure. Id. at 795 (“Arreola did have standing to pursue his lawsuit. Whether he is entitled to relief on any or all of those claims and whether he may serve as an adequate class representative for others asserting such claims are separate questions ....”)

I am mindful that in Bohn v. Boiron, Inc., 11 C 8704, 2013 WL 3975126, at *2-*3 (N.D. Ill. Aug. 1, 2013) (Durkin, J.), the court concluded that the plaintiff lacked Article III standing to obtain an injunction under ICFA on behalf of a class because she disclaimed any likelihood of being personally injured by the defendants’ conduct in the future. Indeed, courts have split on whether a plaintiff who, having unveiled the defendant’s deception, is unlikely to purchase (or affirmatively disavows the intent to purchase) the defendant’s product in the future nevertheless maintains standing to pursue injunctive relief under state consumer protection statutes. See, e.g., Tomasino v. Estee Lauder Companies Inc., 44 F.Supp.3d 251, 255-56 (E.D.N.Y. 2014) (plaintiff lacked standing to seek injunctive relief because she was unlikely to purchase product again); Davidson v. Kimberly-Clark Corp., 14-CV-1783, 2014 WL 3919857, at *5 (N.D.Cal. Aug. 8, 2014). The better view, however, and the one consistent with Arreola, is the one taken by courts that have declined to hold that plaintiffs lacked standing based on the fact that they abandoned the product upon their discovery that it had been deceptively labeled or advertised. See, e.g., Ackerman v. Coca-Cola Co., No. 09 CV 395 (DLI)(RML), 2013 WL 7044866, at *15 (E.D.N.Y July 18, 2013); Henderson v. Gruma Corp., No. 10-cv-4173, 2011 WL 1362188, at *7 (C.D. Ca. Apr. 11, 2011); Larsen v. Trader Joe’s Co., No. C 11-5188, 2012 WL 5458396, at *4 (N.D. Ca. Jun. 14, 2012); Koehler v. Litehouse, Inc., No. 12 CV 04055, 2012 WL 6217635, at *6 (N.D.Cal. Dec.13, 2012). These courts acknowledged the public policy conundrum inherent in the contrary view: the injunc-tive provisions of consumer protection statutes such as ICFA could never be invoked to enjoin deceptive practices if the complaining consumer’s standing dissipated the moment she discovered the alleged deception and could no longer be fooled. While it is true, as Bohn observes, that public policy concerns do not confer Article III standing on a plaintiff who fails to allege an individual injury in fact, I am satisfied that plaintiff has alleged a legally cognizable injury resulting from defendant’s alleged deception, and thus has standing to bring her claims. Whether plaintiff is an appropriate class representative with respect to some or all of these claims is an issue properly decided after discovery and briefing on class certification. See Damasco v. Clearwire Corp., 662 F.3d 891, 897 (7th Cir. 2011) (plaintiffs in putative class actions are entitled to develop factual record before class certification is determined), overruled on other grounds by Chapman v. First Index, Inc., 796 F.3d 783 (7th Cir. 2015).

Defendant’s next argument — that the statements defendants made about the Bedtime Bath Products being “clinically proven” were actually true — is a merits argument outside the scope of what I may appropriately decide on a motion to dismiss. Straining to liken this case to Greifenstein v. Estee Lauder Corp., Inc., No. 2013 WL 3874073 (Jul. 26, 2013) (Chang, J.) (dismissing without prejudice a consumer complaint of false labeling and advertising under ICFA), defendant seeks to recast plaintiffs claims as challenging the “sufficiency” of defendant’s clinical testing. Contrary to defendant’s argument, however, plaintiff does not complain about the “methodology” of defendant’s testing. Rather, she complains that defendant did not clinically test the Bedtime Bath Products at all, but instead tested a “routine,” rendering defendant’s claims that the products had been clinically tested deceptive or misleading. That is unlike the plaintiffs claim in Greifenstein, which rested on allegations that the defendant’s claims were “disproved by competent clinical evidence and based on flawed company-sponsored testing.” Id. at ’I. Indeed, the plaintiff in Greifenstein affirmatively argued that lack of substantiation for the challenged statements, along with the existence of studies allegedly revealing the statements’ falsity, are what rendered the statements false. Id. at *4. Plaintiffs claims are decidedly not of that ilk.

Nor is there merit to defendant’s argument that plaintiffs ICFA claim is not pled with particularity. Plaintiff identifies (and, indeed, attaches to her -complaint) the labels she claims contain false, deceptive, or misleading statements. She states where and when She saw the labels. She alleges that she paid a premium of “at least $1.00” or “at least twenty-five percent” for the Bedtime Bath Products, compared with defendant’s other products not specifically labeled and marketed as helping babies sleep better. No more is needed to satisfy Rule 9(b). See, e.g., Greifenstein, at *4, *7 (allegations containing date and location of purchase sufficient to plead “where” and, “when” of an ICFA claim, and allegations that plaintiff paid an “unwarranted premium” based on false statements sufficient to plead actual damages).

Finally, defendant argues that plaintiffs unjust enrichment claim must be dismissed because it cannot stand in the absence of a viable ICFA claim. Because I conclude that plaintiffs ICFA claim is adequately pled, there is no apparent basis for dismissing her unjust enrichment claim.

Nor am I persuaded that striking plaintiffs class allegations is appropriate. Defendant’s lead argument in this connection is again that plaintiff lacks standing, which I reject for the reasons explained above. Defendant’s remaining arguments — that the proposed class is over-inclusive, that the class claims will require individualized proof, and that some class members may not have relied on the challenged statements, or may have relied on different labels than the ones plaintiff saw — are either premature, do not necessarily preclude class treatment, or both.

For all of these reasons, defendant’s motion is denied. 
      
      . Plaintiff's allegation that defendant "cites to its own 'baby care experts”' in its Infant Sleep Guide, from which it may be possible to infer plaintiff's skepticism about the truth of defendant’s statements based on their source, does not convert her claim to one based on inadequate substantiation in view of her clear allegations elsewhere that defendant "expressly represented that the Products were clinically proven to help baby sleep better,” despite “know[ing].. .contrary to the clear labeling and advertising, [that] the Bedtime Products themselves are not clinically proven.” Complaint at ¶ 24-25.